Named Patient Program brings medicine requests, regulatory documentation, and shipment tracking into a single platform for healthcare professionals and eligible patients to simplify global access to specialty medicines
NOIDA, India — September 9, 2026 — Ikris Pharma Network today announced the launch of Named Patient Program, a digital platform designed to simplify regulatory-compliant access to specialty medicines that are approved in other regulated markets but not yet locally available. The platform is built to help healthcare professionals and eligible patients navigate the Named Patient Import process more efficiently, bringing documentation, order tracking, and communication into one secure interface.
Many innovative therapies already approved and in use in regulated international markets remain inaccessible in other countries due to regulatory timelines, supply limitations, or market access barriers. For patients facing cancer, rare diseases, genetic disorders, and other complex or life-threatening conditions, this delay can materially affect treatment outcomes.
What the Platform Offers:
Named Patient Program is designed around the needs of healthcare professionals and patients navigating time-sensitive treatment decisions. Core capabilities include:
- Secure prescription and KYC document submission
- Digital medicine request management
- Real-time order and shipment tracking
- Request and approval status updates
- Regulatory-compliant import support and documentation assistance
- EU-GMP-compliant sourcing through qualified international supply partners
- Temperature-controlled pharmaceutical logistics
Rather than replacing existing regulatory processes, the platform is designed to improve visibility and reduce coordination friction across the medicine access journey — from initial request through delivery.
Addressing a Growing Need:
Demand for compliant access to globally approved therapies spans oncology, hematology, rare diseases, neurology, immunology, transplant medicine, genetic disorders, and specialty biologics. As precision medicine advances, hospitals and physicians increasingly need efficient pathways to therapies not yet commercially available in their market.
“Access to innovative medicines should be supported by transparency, regulatory compliance, and efficient coordination,” said Bharat Sikri, Director of Ikris Pharma Network. “Through the Named Patient Program, we aim to simplify the Named Patient Import experience for healthcare professionals and eligible patients — from medicine request and regulatory documentation to shipment tracking and delivery — connecting patients with globally approved specialty medicines when timely treatment matters most.”
Availability:
Healthcare professionals, hospitals, and eligible patients can learn more and access the platform.
Contact: https://namedpatientprogram.com/contact-us
About Ikris Pharma Network
Ikris Pharma Network is one of India’s leading Named Patient Medicine Supply companies. The company developed the Named Patient Program, a digital platform built to simplify regulatory-compliant access to globally approved but locally unavailable medicines. Ikris supports patients, physicians, and hospitals through expertise in oncology, rare disease therapies, hematology, transplant medicine, biologics, orphan drugs, regulatory documentation, GDP-compliant logistics, and international pharmaceutical sourcing.
